Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRhythm Technologies, Inc. (NASDAQ: IRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer. As a digital health care company focused on ambulatory cardiac monitoring and data analytics, iRhythm uses its SEC reports to communicate financial performance, risk factors, governance matters, and material corporate events related to its Zio long-term continuous monitoring (LTCM) service and broader operations.
Investors can use this page to review current and historical filings retrieved from the SEC’s EDGAR system, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Recent 8-K filings have covered topics such as quarterly financial results, investor presentations, and amendments to the Executive Change in Control and Severance Policy, which outlines severance payments, COBRA coverage, and equity vesting treatment for senior leaders under specified termination scenarios.
For those analyzing iRhythm’s business in more depth, the company’s periodic reports typically discuss revenue from Zio services, gross margins, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted net loss, and liquidity metrics such as cash, cash equivalents, and marketable securities. These documents also describe how iRhythm accounts for items like stock-based compensation, business transformation costs, and other adjustments that affect non-GAAP results.
Stock Titan enhances access to these filings with AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. Users can quickly identify major changes in financial condition, updates to risk disclosures, and details of insider or executive-related arrangements that appear in forms and exhibits. This combination of real-time filing access and AI-generated insights can support investors, analysts, and other stakeholders who want to understand how iRhythm reports on its digital cardiac monitoring business and corporate governance over time.
iRhythm Holdings, Inc. reported that executive officer Minang Turakhia, its chief medical and scientific officer, executed open-market sales of a total of 4,027 shares of common stock on March 2, 2026 at prices around $128.45 per share. According to the footnote, these shares were sold specifically to cover tax withholding and remittance obligations arising from the vesting of restricted stock units. Following these transactions, Turakhia directly holds 54,906 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Sumi Shrishrimal, EVP and Chief Risk Officer, reported selling a total of 2,830 shares of common stock in three open-market transactions on March 2, 2026 at prices around $128.44 per share. According to the disclosure, these shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs). Following these sales, Shrishrimal directly owned 41,870 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive vice president of strategic business operations Mervin Smith reported selling 1,352 shares of common stock on March 2, 2026 in open‑market transactions at prices around $128.44 per share. The filing states the shares were sold to cover tax withholding obligations from vesting restricted stock units, and Smith held 25,612 shares afterward.
iRhythm Holdings, Inc. executive Chad Patterson, the Chief Commercial & Product Officer, reported open-market sales totaling 4,444 shares of common stock on March 2, 2026, at prices around $128.44 per share.
According to the footnote, these shares were sold to cover tax withholding and remittance obligations tied to vesting Restricted Stock Units, and Patterson continues to hold 58,164 shares directly.
iRhythm Holdings, Inc. executive Patrick Michael Murphy, the company’s CBO and CLO, reported selling 4,357 shares of common stock on March 2, 2026. The shares were sold in several open-market transactions at prices around $128.44 per share to satisfy tax withholding and remittance obligations tied to the vesting of Restricted Stock Units. After these transactions, he continued to hold 63,203 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported two small sales of common stock related to equity compensation. On March 2, 2026, he sold 399 shares at $128.447 per share and 417 shares at $128.452 per share. A footnote states these sales were made to cover tax withholding and remittance obligations tied to vesting Restricted Stock Units, rather than discretionary selling. After these transactions, he directly held 16,706 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Financial Officer Daniel G. Wilson reported open-market sales of company common stock primarily for tax withholding. On March 2, 2026, he sold a total of 3,395 shares of common stock in several open-market transactions at prices around $128.44 per share to cover tax withholding and remittance obligations related to vesting Restricted Stock Units.
After these sales, Wilson directly owned 35,660 shares of iRhythm common stock and indirectly held 100 shares through The Wilson Living Trust dated July 9, 2015, of which he is the trustee.
iRhythm Holdings, Inc. President and CEO Quentin S. Blackford reported selling a total of 13,813 shares of common stock on March 2, 2026 at prices around $128.44 per share. According to the filing, these shares were sold to cover tax withholding obligations tied to vesting restricted stock units. After these transactions, he directly owned 204,155 shares of iRhythm common stock.
Wilson Daniel G. reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. Chief Financial Officer Daniel G. Wilson reported an equity award of 8,361 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock. Following this grant, his directly held common stock position is 39,055 shares.
According to the terms, 25% of the RSUs vest on March 1, 2027, with an additional 25% vesting on each one-year anniversary thereafter, so long as he continues as a service provider through each vesting date. The filing also notes an additional 100 shares of common stock held indirectly through The Wilson Living Trust dated July 9, 2015, for which Mr. Wilson serves as Trustee.
Turakhia Minang reported acquisition or exercise transactions in this Form 4 filing.
iRhythm Holdings, Inc. reported that executive Minang Turakhia received an equity award in the form of Restricted Stock Units (RSUs) covering 10,034 shares of common stock at no cash cost on the grant date. Each RSU represents a right to receive one share if vesting conditions are met.
According to the vesting schedule, 25% of these RSUs vest on March 1, 2027, with the remaining RSUs vesting in equal portions on each one-year anniversary thereafter, as long as Turakhia continues as a service provider through each vesting date. Following this grant, Turakhia directly holds 58,933 shares of common stock.